Robert J Glynn

List of Publications by Year
in descending order

272 papers	44,641 citations	3525 90 h-index	2032 205 g-index
281 all docs	281 docs citations	281 times ranked	43651 citing authors

#	Article	IF	Citations
1	Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease. New England Journal of Medicine, 2017, 377, 1119-1131.	13.9	6,227
2	Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein. New England Journal of Medicine, 2008, 359, 2195-2207.	13.9	5,712
3	Variable Selection for Propensity Score Models. American Journal of Epidemiology, 2006, 163, 1149-1156.	1.6	1,618
4	Effect of interleukin-1β inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial. Lancet, The, 2017, 390, 1833-1842.	6.3	948
5	C-Reactive Protein Adds to the Predictive Value of Total and HDL Cholesterol in Determining Risk of First Myocardial Infarction. Circulation, 1998, 97, 2007-2011.	1.6	904
6	Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial. Lancet, The, 2009, 373, 1175-1182.	6.3	886
7	Low-Dose Methotrexate for the Prevention of Atherosclerotic Events. New England Journal of Medicine, 2019, 380, 752-762.	13.9	886
8	High-dimensional Propensity Score Adjustment in Studies of Treatment Effects Using Health Care Claims Data. Epidemiology, 2009, 20, 512-522.	1.2	870
9	Long-Term, Low-Intensity Warfarin Therapy for the Prevention of Recurrent Venous Thromboembolism. New England Journal of Medicine, 2003, 348, 1425-1434.	13.9	771
10	A combined comorbidity score predicted mortality in elderly patients better than existing scores. Journal of Clinical Epidemiology, 2011, 64, 749-759.	2.4	728
11	Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: an analysis from the JUPITER trial. Lancet, The, 2012, 380, 565-571.	6.3	691
12	A Randomized Trial of Rosuvastatin in the Prevention of Venous Thromboembolism. New England Journal of Medicine, 2009, 360, 1851-1861.	13.9	657
13	Relationship of C-reactive protein reduction to cardiovascular event reduction following treatment with canakinumab: a secondary analysis from the CANTOS randomised controlled trial. Lancet, The, 2018, 391, 319-328.	6.3	628
14	Results of Multivariable Logistic Regression, Propensity Matching, Propensity Adjustment, and Propensity-based Weighting under Conditions of Nonuniform Effect. American Journal of Epidemiology, 2006, 163, 262-270.	1.6	615
15	A review of the application of propensity score methods yielded increasing use, advantages in specific settings, but not substantially different estimates compared with conventional multivariable methods. Journal of Clinical Epidemiology, 2006, 59, 437.e1-437.e24.	2.4	557
16	Cardiovascular Efficacy and Safety of Bococizumab in High-Risk Patients. New England Journal of Medicine, 2017, 376, 1527-1539.	13.9	510
17	Accuracy of medicare claims-based diagnosis of acute myocardial infarction: estimating positive predictive value on the basis of review of hospital records. American Heart Journal, 2004, 148, 99-104.	1.2	489
18	Indications for Propensity Scores and Review of their Use in Pharmacoepidemiology. Basic and Clinical Pharmacology and Toxicology, 2006, 98, 253-259.	1.2	474

#	ARTICLE	IF	CITATIONS
19	Systolic and Diastolic Blood Pressure, Pulse Pressure, and Mean Arterial Pressure as Predictors of Cardiovascular Disease Risk in Men. Hypertension, 2000, 36, 801-807.	1.3	470
20	Anti-Inflammatory Therapy With Canakinumab for the Prevention of Hospitalization for Heart Failure. Circulation, 2019, 139, 1289-1299.	1.6	384
21	Modulation of the interleukin-6 signalling pathway and incidence rates of atherosclerotic events and all-cause mortality: analyses from the Canakinumab Anti-Inflammatory Thrombosis Outcomes Study (CANTOS). European Heart Journal, 2018, 39, 3499-3507.	1.0	375
22	Cholesterol and the Risk of Renal Dysfunction in Apparently Healthy Men. Journal of the American Society of Nephrology: JASN, 2003, 14, 2084-2091.	3.0	352
23	The Comparative Safety of Analgesics in Older Adults With Arthritis. Archives of Internal Medicine, 2010, 170, 1968.	4.3	348
24	Treatment Effects in the Presence of Unmeasured Confounding: Dealing With Observations in the Tails of the Propensity Score Distribution--A Simulation Study. American Journal of Epidemiology, 2010, 172, 843-854.	1.6	343
25	Comparison of Risk Factors for the Competing Risks of Coronary Heart Disease, Stroke, and Venous Thromboembolism. American Journal of Epidemiology, 2005, 162, 975-982.	1.6	338
26	Lipid-Reduction Variability and Antidrug-Antibody Formation with Bococizumab. New England Journal of Medicine, 2017, 376, 1517-1526.	13.9	307
27	Alcohol Consumption and Plasma Concentration of C-Reactive Protein. Circulation, 2003, 107, 443-447.	1.6	305
28	Measuring Frailty in Medicare Data: Development and Validation of a Claims-Based Frailty Index. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2018, 73, 980-987.	1.7	303
29	Effects of vitamin E on stroke subtypes: meta-analysis of randomised controlled trials. BMJ: British Medical Journal, 2010, 341, c5702-c5702.	2.4	299
30	Confounding Control in Healthcare Database Research. Medical Care, 2010, 48, S114-S120.	1.1	291
31	Influence of Systolic and Diastolic Blood Pressure on the Risk of Incident Atrial Fibrillation in Women. Circulation, 2009, 119, 2146-2152.	1.6	285
32	Rationale and design of the Pemafibrate to Reduce Cardiovascular Outcomes by Reducing Triglycerides in Patients with Diabetes (PROMINENT) study. American Heart Journal, 2018, 206, 80-93.	1.2	276
33	Improved Comorbidity Adjustment for Predicting Mortality in Medicare Populations. Health Services Research, 2003, 38, 1103-1120.	1.0	273
34	The Effects of Initial Drug Choice and Comorbidity on Antihypertensive Therapy Compliance Results From a Population-Based Study in the Elderly. American Journal of Hypertension, 1997, 10, 697-704.	1.0	246
35	Academic Detailing to Improve Use of Broad-Spectrum Antibiotics at an Academic Medical Center. Archives of Internal Medicine, 2001, 161, 1897.	4.3	240
36	Plasma Concentration of C-Reactive Protein and the Calculated Framingham Coronary Heart Disease Risk Score. Circulation, 2003, 108, 161-165.	1.6	240

#	Article	IF	Citations
37	Anti-Inflammatory Therapy With Canakinumab for the Prevention and Management of Diabetes. Journal of the American College of Cardiology, 2018, 71, 2392-2401.	1.2	236
38	Current and Remote Blood Pressure and Cognitive Decline. JAMA - Journal of the American Medical Association, 1999, 281, 438.	3.8	233
39	C-Reactive protein levels among women of various ethnic groups living in the United States (from the) Tj ETQq1 1 0.784314 rgBT /Ov	0.7	231
40	Increasing Levels of Restriction in Pharmacoepidemiologic Database Studies of Elderly and Comparison With Randomized Trial Results. Medical Care, 2007, 45, S131-S142.	1.1	228
41	Maternal and Paternal History of Myocardial Infarction and Risk of Cardiovascular Disease in Men and Women. Circulation, 2001, 104, 393-398.	1.6	221
42	HDL cholesterol and residual risk of first cardiovascular events after treatment with potent statin therapy: an analysis from the JUPITER trial. Lancet, The, 2010, 376, 333-339.	6.3	221
43	Use of Medications by Persons 65 and Over: Data From the Established Populations for Epidemiologic Studies of the Elderly. Journal of Gerontology, 1992, 47, M137-M144.	2.0	218
44	Pulse Pressure and Mortality in Older People. Archives of Internal Medicine, 2000, 160, 2765.	4.3	218
45	Zolpidem Use and Hip Fractures in Older People. Journal of the American Geriatrics Society, 2001, 49, 1685-1690.	1.3	218
46	Statin Adherence and Risk of Accidents. Circulation, 2009, 119, 2051-2057.	1.6	217
47	Effects of Adjusting for Instrumental Variables on Bias and Precision of Effect Estimates. American Journal of Epidemiology, 2011, 174, 1213-1222.	1.6	205
48	Rosuvastatin for Primary Prevention in Older Persons With Elevated C-Reactive Protein and Low to Average Low-Density Lipoprotein Cholesterol Levels: Exploratory Analysis of a Randomized Trial. Annals of Internal Medicine, 2010, 152, 488.	2.0	198
49	Evaluating uses of data mining techniques in propensity score estimation: a simulation study. Pharmacoepidemiology and Drug Safety, 2008, 17, 546-555.	0.9	195
50	Efficacy of Rosuvastatin Among Men and Women With Moderate Chronic Kidney Disease and Elevated High-Sensitivity C-Reactive Protein. Journal of the American College of Cardiology, 2010, 55, 1266-1273.	1.2	191
51	Inhibition of Interleukin-1Î² by Canakinumab and Cardiovascular Outcomes in Patients With ChronicÂKidney Disease. Journal of the American College of Cardiology, 2018, 71, 2405-2414.	1.2	186
52	Adjusting Effect Estimates for Unmeasured Confounding with Validation Data using Propensity Score Calibration. American Journal of Epidemiology, 2005, 162, 279-289.	1.6	185
53	Cholesterol Efflux Capacity, High-Density Lipoprotein Particle Number, and Incident Cardiovascular Events. Circulation, 2017, 135, 2494-2504.	1.6	180
54	Recovery of Ventricular Function after Myocardial Infarction in the Reperfusion Era: The Healing and Early Afterload Reducing Therapy Study. Annals of Internal Medicine, 2001, 134, 451.	2.0	179

#	ARTICLE	IF	CITATIONS
55	Ways of measuring rates of recurrent events. BMJ: British Medical Journal, 1996, 312, 364-367.	2.4	177
56	Emulating Randomized Clinical Trials With Nonrandomized Real-World Evidence Studies. Circulation, 2021, 143, 1002-1013.	1.6	174
57	Paradoxical Relations of Drug Treatment with Mortality in Older Persons. Epidemiology, 2001, 12, 682-689.	1.2	170
58	A Randomized Study of How Physicians Interpret Research Funding Disclosures. New England Journal of Medicine, 2012, 367, 1119-1127.	13.9	165
59	Improvements in Long-Term Mortality After Myocardial Infarction and Increased Use of Cardiovascular Drugs After Discharge. Journal of the American College of Cardiology, 2008, 51, 1247-1254.	1.2	164
60	Analytic Strategies to Adjust Confounding using Exposure Propensity Scores and Disease Risk Scores: Nonsteroidal Antiinflammatory Drugs and Short-term Mortality in the Elderly. American Journal of Epidemiology, 2005, 161, 891-898.	1.6	155
61	Blood pressure and risk of developing type 2 diabetes mellitus: The Women's Health Study. European Heart Journal, 2007, 28, 2937-2943.	1.0	153
62	The neutrophil–lymphocyte ratio and incident atherosclerotic events: analyses from five contemporary randomized trials. European Heart Journal, 2021, 42, 896-903.	1.0	152
63	Effect of physical activity on serum C-reactive protein. American Journal of Cardiology, 2004, 93, 221-225.	0.7	151
64	Covariate Selection in High-Dimensional Propensity Score Analyses of Treatment Effects in Small Samples. American Journal of Epidemiology, 2011, 173, 1404-1413.	1.6	149
65	Instrumental variables I: instrumental variables exploit natural variation in nonexperimental data to estimate causal relationships. Journal of Clinical Epidemiology, 2009, 62, 1226-1232.	2.4	146
66	Statins and the Risk of Lung, Breast, and Colorectal Cancer in the Elderly. Circulation, 2007, 115, 27-33.	1.6	145
67	Relation of Baseline High-Sensitivity C-Reactive Protein Level to Cardiovascular Outcomes With Rosuvastatin in the Justification for Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER). American Journal of Cardiology, 2010, 106, 204-209.	0.7	136
68	Cardiovascular outcomes associated with canagliflozin versus other non-gliflozin antidiabetic drugs: population based cohort study. BMJ: British Medical Journal, 2018, 360, k119.	2.4	132
69	Risk Factors for Mortality in the Nurses' Health Study: A Competing Risks Analysis. American Journal of Epidemiology, 2011, 173, 319-329.	1.6	130
70	Validation of a Claims-Based Frailty Index Against Physical Performance and Adverse Health Outcomes in the Health and Retirement Study. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2019, 74, 1271-1276.	1.7	130
71	Falls in Elderly Patients With Glaucoma. JAMA Ophthalmology, 1991, 109, 205.	2.6	129
72	Accounting for the Correlation Between Fellow Eyes in Regression Analysis. JAMA Ophthalmology, 1992, 110, 381.	2.6	129

#	Article	IF	Citations
73	Number Needed to Treat With Rosuvastatin to Prevent First Cardiovascular Events and Death Among Men and Women With Low Low-Density Lipoprotein Cholesterol and Elevated High-Sensitivity C-Reactive Protein. Circulation: Cardiovascular Quality and Outcomes, 2009, 2, 616-623.	0.9	128
74	Adverse Effects of Low-Dose Methotrexate. Annals of Internal Medicine, 2020, 172, 369.	2.0	126
75	Multiple Imputation in Mixture Models for Nonignorable Nonresponse with Follow-ups. Journal of the American Statistical Association, 1993, 88, 984-993.	1.8	121
76	Effects of Random Allocation to Vitamin E Supplementation on the Occurrence of Venous Thromboembolism. Circulation, 2007, 116, 1497-1503.	1.6	117
77	Development of Predictive Models for Long-Term Cardiovascular Risk Associated With Systolic and Diastolic Blood Pressure. Hypertension, 2002, 39, 105-110.	1.3	116
78	Selective prescribing led to overestimation of the benefits of lipid-lowering drugs. Journal of Clinical Epidemiology, 2006, 59, 819-828.	2.4	115
79	Body Mass Index. JAMA Ophthalmology, 1995, 113, 1131.	2.6	114
80	Baseline Characteristics of Participants in the JUPITER Trial, A Randomized Placebo-Controlled Primary Prevention Trial of Statin Therapy Among Individuals With Low Low-Density Lipoprotein Cholesterol and Elevated High-Sensitivity C-Reactive Protein. American Journal of Cardiology, 2007, 100, 1659-1664.	0.7	113
81	Evaluating the Use of Nonrandomized Real‐World Data Analyses for Regulatory Decision Making. Clinical Pharmacology and Therapeutics, 2019, 105, 867-877.	2.3	112
82	The implications of propensity score variable selection strategies in pharmacoepidemiology: an empirical illustration. Pharmacoepidemiology and Drug Safety, 2011, 20, 551-559.	0.9	111
83	Regression Methods when the Eye is the Unit of Analysis. Ophthalmic Epidemiology, 2012, 19, 159-165.	0.8	108
84	Risk of high-grade cervical dysplasia and cervical cancer in women with systemic inflammatory diseases: a population-based cohort study. Annals of the Rheumatic Diseases, 2015, 74, 1360-1367.	0.5	108
85	Tutorial on Biostatistics: Linear Regression Analysis of Continuous Correlated Eye Data. Ophthalmic Epidemiology, 2017, 24, 130-140.	0.8	108
86	Prospective Study of Moderate Alcohol Consumption and Risk of Peripheral Arterial Disease in US Male Physicians. Circulation, 1997, 95, 577-580.	1.6	103
87	Adjusting for Unmeasured Confounders in Pharmacoepidemiologic Claims Data Using External Information. Epidemiology, 2005, 16, 17-24.	1.2	101
88	Atherogenic Lipoprotein Subfractions Determined by Ion Mobility and First Cardiovascular Events After Random Allocation to High-Intensity Statin or Placebo. Circulation, 2015, 132, 2220-2229.	1.6	101
89	Identification of Racial Inequities in Access to Specialized Inpatient Heart Failure Care at an Academic Medical Center. Circulation: Heart Failure, 2019, 12, e006214.	1.6	100
90	Atherogenic Lipoprotein Determinants of Cardiovascular Disease and Residual Risk Among Individuals With Low Low‐Density Lipoprotein Cholesterol. Journal of the American Heart Association, 2017, 6, .	1.6	98

#	Article	IF	Citations
91	Circulating N-Linked Glycoprotein Acetyls and Longitudinal Mortality Risk. Circulation Research, 2016, 118, 1106-1115.	2.0	97
92	Primary Prevention With Statin Therapy in the Elderly. Circulation, 2017, 135, 1979-1981.	1.6	97
93	Matching Weights to Simultaneously Compare Three Treatment Groups. Epidemiology, 2017, 28, 387-395.	1.2	97
94	Risk of cardiovascular events among women with high normal blood pressure or blood pressure progression: prospective cohort study. BMJ: British Medical Journal, 2007, 335, 432.	2.4	94
95	On-Treatment Non–High-Density Lipoprotein Cholesterol, Apolipoprotein B, Triglycerides, and Lipid Ratios in Relation to Residual Vascular Risk After Treatment With Potent Statin Therapy. Journal of the American College of Cardiology, 2012, 59, 1521-1528.	1.2	90
96	Role of disease risk scores in comparative effectiveness research with emerging therapies. Pharmacoepidemiology and Drug Safety, 2012, 21, 138-147.	0.9	87
97	Relations of body fat distribution and height with cataract in men. American Journal of Clinical Nutrition, 2000, 72, 1495-1502.	2.2	86
98	Vitamin E and C supplementation and risk of cancer in men: posttrial follow-up in the Physicians' Health Study II randomized trial , , ,. American Journal of Clinical Nutrition, 2014, 100, 915-923.	2.2	83
99	Trends in serum uric acid levels. Arthritis and Rheumatism, 1983, 26, 87-93.	6.7	82
100	Tracking of High-Sensitivity C-Reactive Protein after an Initially Elevated Concentration: The JUPITER Study. Clinical Chemistry, 2009, 55, 305-312.	1.5	82
101	Dipeptidyl peptidase-4 inhibitors in type 2 diabetes may reduce the risk of autoimmune diseases: a population-based cohort study. Annals of the Rheumatic Diseases, 2015, 74, 1968-1975.	0.5	82
102	Measuring Frailty in Administrative Claims Data: Comparative Performance of Four Claims-Based Frailty Measures in the U.S. Medicare Data. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2020, 75, 1120-1125.	1.7	82
103	Association of Lipid, Inflammatory, and Metabolic Biomarkers With Age at Onset for Incident Coronary Heart Disease in Women. JAMA Cardiology, 2021, 6, 437.	3.0	82
104	Histological Pattern of Mandibular Invasion by Oral Squamous Cell Carcinoma. Laryngoscope, 2000, 110, 65-72.	1.1	81
105	Tutorial on Biostatistics: Statistical Analysis for Correlated Binary Eye Data. Ophthalmic Epidemiology, 2018, 25, 1-12.	0.8	79
106	Effect of Vitamin D and Omega-3 Fatty Acid Supplementation on Kidney Function in Patients With Type 2 Diabetes. JAMA - Journal of the American Medical Association, 2019, 322, 1899.	3.8	77
107	Prospective Cohort Study of Antioxidant Vitamin Supplement Use and the Risk of Age-related Maculopathy. American Journal of Epidemiology, 1999, 149, 476-484.	1.6	76
108	Nonrandomized Real–World Evidence to Support Regulatory Decision Making: Process for a Randomized Trial Replication Project. Clinical Pharmacology and Therapeutics, 2020, 107, 817-826.	2.3	76

#	Article	IF	Citations
109	Revision Stapedectomy: Intraoperative Findings, Results, and Review of the Literature. Laryngoscope, 1997, 107, 1185-1192.	1.1	75
110	Socioeconomic status, blood pressure progression, and incident hypertension in a prospective cohort of female health professionals. European Heart Journal, 2009, 30, 1378-1384.	1.0	75
111	Effects of Xanthine Oxidase Inhibitors on Cardiovascular Disease in Patients with Gout: AÂCohort Study. American Journal of Medicine, 2015, 128, 653.e7-653.e16.	0.6	75
112	Discordance between Circulating Atherogenic Cholesterol Mass and Lipoprotein Particle Concentration in Relation to Future Coronary Events in Women. Clinical Chemistry, 2017, 63, 870-879.	1.5	74
113	Relationship of Interleukin-1Î² Blockade With Incident Gout and Serum Uric Acid Levels. Annals of Internal Medicine, 2018, 169, 535.	2.0	74
114	A Randomized Trial of Beta Carotene and Age-Related Cataract in US Physicians. JAMA Ophthalmology, 2003, 121, 372.	2.6	72
115	Comparison of interleukin-6, C-reactive protein, and low-density lipoprotein cholesterol as biomarkers of residual risk in contemporary practice: secondary analyses from the Cardiovascular Inflammation Reduction Trial. European Heart Journal, 2020, 41, 2952-2961.	1.0	72
116	Different Methods of Balancing Covariates Leading to Different Effect Estimates in the Presence of Effect Modification. American Journal of Epidemiology, 2009, 169, 909-917.	1.6	71
117	Predisposing Factors Associated With Development of Persistent Compared With Paroxysmal Atrial Fibrillation. Journal of the American Heart Association, 2014, 3, e000916.	1.6	69
118	Effects of Interleukin-1Î² Inhibition on Blood Pressure, Incident Hypertension, and Residual Inflammatory Risk. Hypertension, 2020, 75, 477-482.	1.3	69
119	Adjustments for Unmeasured Confounders in Pharmacoepidemiologic Database Studies Using External Information. Medical Care, 2007, 45, S158-S165.	1.1	68
120	Adherence to Aspirin in the Prevention of Myocardial Infarction. Archives of Internal Medicine, 1994, 154, 2649.	4.3	66
121	Effect of Low-Dose Aspirin on the Occurrence of Venous Thromboembolism. Annals of Internal Medicine, 2007, 147, 525.	2.0	66
122	Methods to evaluate risks for composite end points and their individual components. Journal of Clinical Epidemiology, 2004, 57, 113-122.	2.4	63
123	A Medicare database review found that physician preferences increasingly outweighed patient characteristics as determinants of first-time prescriptions for COX-2 inhibitors. Journal of Clinical Epidemiology, 2005, 58, 98-102.	2.4	62
124	Design of Cluster-Randomized Trials of Quality Improvement Interventions Aimed at Medical Care Providers. Medical Care, 2007, 45, S38-S43.	1.1	62
125	Efficacy of Tympanomastoid Surgery for Control of Infection in Active Chronic Otitis Media. Laryngoscope, 1997, 107, 872-877.	1.1	61
126	Burden of smoking on cause-specific mortality: application to the Nurses' Health Study. Tobacco Control, 2010, 19, 248-254.	1.8	61

#	Article	IF	Citations
127	Breast Cancer Risk Prediction with Heterogeneous Risk Profiles According to Breast Cancer Tumor Markers. American Journal of Epidemiology, 2013, 178, 296-308.	1.6	61
128	Residual Risk of Atherosclerotic Cardiovascular Events in Relation to Reductions in Very‐Low‐Density Lipoproteins. Journal of the American Heart Association, 2017, 6, .	1.6	61
129	Effects of Multivitamin Supplement on Cataract and Age-Related Macular Degeneration in a Randomized Trial of Male Physicians. Ophthalmology, 2014, 121, 525-534.	2.5	60
130	Prospective study of body size throughout the life-course and the incidence of endometrial cancer among premenopausal and postmenopausal women. International Journal of Cancer, 2015, 137, 625-637.	2.3	60
131	Benzodiazepines and risk of all cause mortality in adults: cohort study. BMJ: British Medical Journal, 2017, 358, j2941.	2.4	60
132	The effect of rosuvastatin on incident pneumonia: results from the JUPITER trial. Cmaj, 2012, 184, E367-E372.	0.9	59
133	Evaluating bococizumab, a monoclonal antibody to PCSK9, on lipid levels and clinical events in broad patient groups with and without prior cardiovascular events: Rationale and design of the Studies of PCSK9 Inhibition and the Reduction of vascular Events (SPIRE) Lipid Lowering and SPIRE Cardiovascular Outcomes Trials. American Heart Journal, 2016, 178, 135-144.	1.2	58
134	Studies with Many Covariates and Few Outcomes. Epidemiology, 2014, 25, 268-278.	1.2	57
135	The Association between Statin use and Outcomes Potentially Attributable to an Unhealthy Lifestyle in Older Adults. Value in Health, 2011, 14, 513-520.	0.1	55
136	Statin Therapy and Risk of Fracture. JAMA Internal Medicine, 2015, 175, 171.	2.6	53
137	Association of Lipoproteins, Insulin Resistance, and Rosuvastatin With Incident Type 2 Diabetes Mellitus. JAMA Cardiology, 2016, 1, 136.	3.0	53
138	Standardized rates of recurrent outcomes. Statistics in Medicine, 1994, 13, 1781-1791.	0.8	52
139	Rosuvastatin for Primary Prevention Among Individuals With Elevated High-Sensitivity C-Reactive Protein and 5% to 10% and 10% to 20% 10-Year Risk. Circulation: Cardiovascular Quality and Outcomes, 2010, 3, 447-452.	0.9	52
140	Sodium–Glucose Cotransporter-2 Inhibitors Versus Glucagon-like Peptide-1 Receptor Agonists and the Risk for Cardiovascular Outcomes in Routine Care Patients With Diabetes Across Categories of Cardiovascular Disease. Annals of Internal Medicine, 2021, 174, 1528-1541.	2.0	52
141	Calendar time–specific propensity scores and comparative effectiveness research for stage III colon cancer chemotherapy. Pharmacoepidemiology and Drug Safety, 2013, 22, 810-818.	0.9	50
142	Regularized Regression Versus the High-Dimensional Propensity Score for Confounding Adjustment in Secondary Database Analyses. American Journal of Epidemiology, 2015, 182, 651-659.	1.6	50
143	Using propensity scores to estimate effects of treatment initiation decisions: State of the science. Statistics in Medicine, 2021, 40, 1718-1735.	0.8	50
144	Kinesin-Like Protein 6 (KIF6) Polymorphism and the Efficacy of Rosuvastatin in Primary Prevention. Circulation: Cardiovascular Genetics, 2011, 4, 312-317.	5.1	48

#	Article	IF	Citations
145	Frailty and Clinical Outcomes of Direct Oral Anticoagulants Versus Warfarin in Older Adults With Atrial Fibrillation. Annals of Internal Medicine, 2021, 174, 1214-1223.	2.0	48
146	Risk Factors for Non‐Insulin‐Dependent Diabetes Mellitus Requiring Treatment in the Elderly. Journal of the American Geriatrics Society, 1994, 42, 1235-1240.	1.3	47
147	Risk of Cardiovascular Outcomes in Patients With Type 2 Diabetes After Addition of SGLT2 Inhibitors Versus Sulfonylureas to Baseline GLP-1RA Therapy. Circulation, 2021, 143, 770-779.	1.6	47
148	Ten-Year Trends of Cardiovascular Drug Use After Myocardial Infarction Among Community-Dwelling Persons ≥65 Years of Age. American Journal of Cardiology, 2007, 100, 1061-1067.	0.7	45
149	Association Between Patient-Centered Medical Homes and Adherence to Chronic Disease Medications. Annals of Internal Medicine, 2017, 166, 81.	2.0	45
150	A multicomponent frailty intervention for socioeconomically vulnerable older adults: a designed-delay study. Clinical Interventions in Aging, 2018, Volume 13, 1799-1814.	1.3	45
151	Interval estimation for rank correlation coefficients based on the probit transformation with extension to measurement error correction of correlated ranked data. Statistics in Medicine, 2007, 26, 633-646.	0.8	44
152	Circulating N‐Linked Glycoprotein Side‐Chain Biomarker, Rosuvastatin Therapy, and Incident Cardiovascular Disease: An Analysis From the JUPITER Trial. Journal of the American Heart Association, 2016, 5, .	1.6	44
153	Estimating the Variance of Standardized Rates of Recurrent Events, with Application to Hospitalizations among the Elderly in New England. American Journal of Epidemiology, 1993, 137, 776-786.	1.6	43
154	Blood Pressure and Risk of Secondary Cardiovascular Events in Women. Circulation, 2004, 109, 1623-1629.	1.6	42
155	Evaluation of Risk Factors for Cataract Types in a Competing Risks Framework. Ophthalmic Epidemiology, 2009, 16, 98-106.	0.8	42
156	Racial and Socioeconomic Differences in Eye Care Utilization among Medicare Beneficiaries with Glaucoma. Ophthalmology, 2022, 129, 397-405.	2.5	42
157	Medication Synchronization Programs Improve Adherence To Cardiovascular Medications And Health Care Use. Health Affairs, 2018, 37, 125-133.	2.5	41
158	Out-of-system Care and Recording of Patient Characteristics Critical for Comparative Effectiveness Research. Epidemiology, 2018, 29, 356-363.	1.2	41
159	Evaluation of a mandatory phishing training program for high-risk employees at a US healthcare system. Journal of the American Medical Informatics Association: JAMIA, 2019, 26, 547-552.	2.2	41
160	Comparison of alternative regression models for paired binary data. Statistics in Medicine, 1994, 13, 1023-1036.	0.8	40
161	Agreement between Drug Treatment Data and a Discharge Diagnosis of Diabetes Mellitus in the Elderly. American Journal of Epidemiology, 1999, 149, 541-549.	1.6	40
162	Race, ethnicity, and the efficacy of rosuvastatin in primary prevention: The Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER) trial. American Heart Journal, 2011, 162, 106-114.e2.	1.2	40

#	Article	IF	Citations
163	Identifying Patients With High Data Completeness to Improve Validity of Comparative Effectiveness Research in Electronic Health Records Data. Clinical Pharmacology and Therapeutics, 2018, 103, 899-905.	2.3	40
164	A Comprehensive Model of Colorectal Cancer by Risk Factor Status and Subsite Using Data From the Nursesâ€™ Health Study. American Journal of Epidemiology, 2017, 185, 224-237.	1.6	39
165	Assessment of Employee Susceptibility to Phishing Attacks at US Health Care Institutions. JAMA Network Open, 2019, 2, e190393.	2.8	39
166	The Cost-Effectiveness of C-Reactive Protein Testing and Rosuvastatin Treatment for Patients With Normal Cholesterol Levels. Journal of the American College of Cardiology, 2011, 57, 784-791.	1.2	38
167	Age-Related Cataract in Men in the Selenium and Vitamin E Cancer Prevention Trial Eye Endpoints Study. JAMA Ophthalmology, 2015, 133, 17.	1.4	38
168	Definition of Race and Ethnicity in Older People in Medicare and Medicaid. Journal of the American Geriatrics Society, 1999, 47, 730-733.	1.3	37
169	Effects of Interleukin-1Î² Inhibition on Incident Anemia. Annals of Internal Medicine, 2020, 172, 523.	2.0	37
170	An Evaluation of Candidate Genes of Inflammation and Thrombosis in Relation to the Risk of Venous Thromboembolism. Circulation: Cardiovascular Genetics, 2009, 2, 57-62.	5.1	36
171	Vitamin E and Age-Related Macular Degeneration in a Randomized Trial of Women. Ophthalmology, 2010, 117, 1163-1168.	2.5	35
172	Dipeptidyl peptidase-4 inhibitors do not increase the risk of cardiovascular events in type 2 diabetes: a cohort study. Acta Diabetologica, 2014, 51, 1015-1023.	1.2	35
173	A Prospective Study of Blood Pressure and Risk of Cataract in Men. Annals of Epidemiology, 2001, 11, 104-110.	0.9	34
174	Explained variation in a model of therapeutic decision making is partitioned across patient, physician, and clinic factors. Journal of Clinical Epidemiology, 2006, 59, 18-25.	2.4	34
175	Calculating Sensitivity, Specificity, and Predictive Values for Correlated Eye Data. , 2020, 61, 29.		34
176	Natriuretic Peptide Precursor A Gene Polymorphisms and Risk of Blood Pressure Progression and Incident Hypertension. Hypertension, 2007, 50, 1114-1119.	1.3	33
177	Risk factors for incident atrial fibrillation with and without left atrial enlargement in women. International Journal of Cardiology, 2013, 168, 1894-1899.	0.8	32
178	Propensity Score Weighting and Trimming Strategies for Reducing Variance and Bias of Treatment Effect Estimates: A Simulation Study. American Journal of Epidemiology, 2021, 190, 1659-1670.	1.6	31
179	Association of N-Linked Glycoprotein Acetyls and Colorectal Cancer Incidence and Mortality. PLoS ONE, 2016, 11, e0165615.	1.1	31
180	Risk of Venous Thromboembolism in Patients with Rheumatoid Arthritis: Initiating Disease-Modifying Antirheumatic Drugs. American Journal of Medicine, 2015, 128, 539.e7-539.e17.	0.6	30

#	Article	IF	Citations
181	Awareness, Accuracy, and Predictive Validity of Self-Reported Cholesterol in Women. Journal of General Internal Medicine, 2007, 22, 606-613.	1.3	29
182	The JUPITER Trial: Responding to the Critics. American Journal of Cardiology, 2010, 106, 1351-1356.	0.7	29
183	Disease associations with isolated elevations of each of the four IgG subclasses. Seminars in Arthritis and Rheumatism, 2017, 47, 276-280.	1.6	29
184	Realâ€World Evidence for Assessing Pharmaceutical Treatments in the Context of COVIDâ€19. Clinical Pharmacology and Therapeutics, 2021, 109, 816-828.	2.3	29
185	Prediction of rates of thromboembolic and major bleeding outcomes with dabigatran or warfarin among patients with atrial fibrillation: new initiator cohort study. BMJ, The, 2016, 353, i2607.	3.0	28
186	Emulation Differences vs. Biases When Calibrating Realâ€World Evidence Findings Against Randomized Controlled Trials. Clinical Pharmacology and Therapeutics, 2020, 107, 735-737.	2.3	27
187	Assessment of myocardial viability and left ventricular function in patients supported by a left ventricular assist device. Journal of Heart and Lung Transplantation, 2014, 33, 372-381.	0.3	26
188	Association Between Highâ€Sensitivity Câ€Reactive Protein and Total Stroke by Hypertensive Status Among Men. Journal of the American Heart Association, 2015, 4, e002073.	1.6	26
189	Prediction Score for Anticoagulation Control Quality Among Older Adults. Journal of the American Heart Association, 2017, 6, .	1.6	26
190	Association of tobacco use and cessation with coronary atherosclerosis. Atherosclerosis, 2017, 257, 201-207.	0.4	25
191	Group IIA Secretory Phospholipase A$_2$, Vascular Inflammation, and Incident Cardiovascular Disease. Arteriosclerosis, Thrombosis, and Vascular Biology, 2019, 39, 1182-1190.	1.1	25
192	Multinomial Extension of Propensity Score Trimming Methods: A Simulation Study. American Journal of Epidemiology, 2019, 188, 609-616.	1.6	25
193	Performance of Disease Risk Score Matching in Nested Case-Control Studies: A Simulation Study. American Journal of Epidemiology, 2016, 183, 949-957.	1.6	24
194	Plasma NT1 Tau is a Specific and Early Marker of Alzheimer's Disease. Annals of Neurology, 2020, 88, 878-892.	2.8	24
195	Trends in First-Line Glucose-Lowering Drug Use in Adults With Type 2 Diabetes in Light of Emerging Evidence for SGLT-2i and GLP-1RA. Diabetes Care, 2021, 44, 1774-1782.	4.3	24
196	Folic Acid, Vitamin B$_6$, and Vitamin B$_{12}$ in Combination and Age-Related Cataract in a Randomized Trial of Women. Ophthalmic Epidemiology, 2016, 23, 32-39.	0.8	23
197	Multiple Imputation in Mixture Models for Nonignorable Nonresponse With Follow-ups. Journal of the American Statistical Association, 1993, 88, 984.	1.8	22
198	Comparison of high-dimensional confounder summary scores in comparative studies of newly marketed medications. Journal of Clinical Epidemiology, 2016, 76, 200-208.	2.4	21

#	Article	IF	Citations
199	Modification of Increasing Systolic Blood Pressure in the Elderly during the 1980s. American Journal of Epidemiology, 1993, 138, 365-379.	1.6	20
200	Dynamics of plasma biomarkers in Down syndrome: the relative levels of AÎ²42 decrease with age, whereas NT1 tau and NfL increase. Alzheimer's Research and Therapy, 2020, 12, 27.	3.0	20
201	Tutorial on Biostatistics: Longitudinal Analysis of Correlated Continuous Eye Data. Ophthalmic Epidemiology, 2021, 28, 3-20.	0.8	20
202	Cardiovascular Outcomes in Patients Initiating First-Line Treatment of Type 2 Diabetes With Sodiumâ€"Glucose Cotransporter-2 Inhibitors Versus Metformin. Annals of Internal Medicine, 2022, 175, 927-937.	2.0	20
203	Blood Pressure Lowering and Life Expectancy Based on a Markov Model of Cardiovascular Events. Hypertension, 2003, 42, 885-890.	1.3	19
204	Multivitamin Use and the Risk of Cardiovascular Disease in Men. Journal of Nutrition, 2016, 146, 1235-1240.	1.3	19
205	Comparison of alternative approaches to trim subjects in the tails of the propensity score distribution. Pharmacoepidemiology and Drug Safety, 2019, 28, 1290-1298.	0.9	19
206	Occurrence of inflammatory bowel disease in patients with chronic inflammatory skin diseases: a cohort study. British Journal of Dermatology, 2022, 187, 692-703.	1.4	19
207	Counting Recurrent Events in Cancer Research. Journal of the National Cancer Institute, 2001, 93, 488-489.	3.0	18
208	Real-World Data Analytics Fit for Regulatory Decision-Making. American Journal of Law and Medicine, 2018, 44, 197-217.	0.5	18
209	Adverse Effects of Lowâ€Dose Methotrexate in a Randomized Doubleâ€Blind Placeboâ€Controlled Trial: Adjudicated Hematologic and Skin Cancer Outcomes in the Cardiovascular Inflammation Reduction Trial. ACR Open Rheumatology, 2020, 2, 697-704.	0.9	18
210	<p>External Validation of an Algorithm to Identify Patients with High Data-Completeness in Electronic Health Records for Comparative Effectiveness Research</p>. Clinical Epidemiology, 2020, Volume 12, 133-141.	1.5	18
211	JNC 7 Category and Risk of Cardiovascular Death in Men: Are There Differences by Age?. The American Journal of Geriatric Cardiology, 2005, 14, 126-133.	0.7	17
212	Reducing Bias Amplification in the Presence of Unmeasured Confounding through Out-of-Sample Estimation Strategies for the Disease Risk Score. Journal of Causal Inference, 2014, 2, 131-146.	0.5	17
213	Dimension reduction and shrinkage methods for high dimensional disease risk scores in historical data. Emerging Themes in Epidemiology, 2016, 13, 5.	1.2	17
214	Classifying medical histories in US Medicare beneficiaries using fixed vs allâ€available lookâ€back approaches. Pharmacoepidemiology and Drug Safety, 2018, 27, 771-780.	0.9	17
215	A Caseâ€Crossoverâ€"Based Screening Approach to Identifying Clinically Relevant Drugâ€"Drug Interactions in Electronic Healthcare Data. Clinical Pharmacology and Therapeutics, 2019, 106, 238-244.	2.3	17
216	Rosuvastatin for the prevention of venous thromboembolism: a pooled analysis of the HOPE-3 and JUPITER randomized controlled trials. Cardiovascular Research, 2022, 118, 897-903.	1.8	17

#	ARTICLE	IF	CITATIONS
217	Coprescription of Opioids With Other Medications and Risk of Opioid Overdose. Clinical Pharmacology and Therapeutics, 2021, 110, 1011-1017.	2.3	16
218	The â€œDry-Runâ€•Analysis: A Method for Evaluating Risk Scores for Confounding Control. American Journal of Epidemiology, 2017, 185, 842-852.	1.6	15
219	Lowering of hemoglobin A1C and risk of cardiovascular outcomes and all-cause mortality, a meta-regression analysis. Journal of Diabetes and Its Complications, 2020, 34, 107704.	1.2	15
220	<p>Risk Factors for Heart Failure with Preserved or Reduced Ejection Fraction Among Medicare Beneficiaries: Application of Competing Risks Analysis and Gradient Boosted Model</p>. Clinical Epidemiology, 2020, Volume 12, 607-616.	1.5	15
221	Sturmer et al. Respond to "Propensity Score Methods in Epidemiology". American Journal of Epidemiology, 2007, 165, 1122-1123.	1.6	14
222	Risk of Incident Osteoarthritis of the Hand in Statin Initiators: A Sequential Cohort Study. Arthritis Care and Research, 2018, 70, 1795-1805.	1.5	14
223	Rationale and design of the Novel Uses of adaptive Designs to Guide provider Engagement in Electronic Health Records (NUDGE-EHR) pragmatic adaptive randomized trial: a trial protocol. Implementation Science, 2021, 16, 9.	2.5	14
224	Promises and Limitations of Mendelian Randomization for Evaluation of Biomarkers. Clinical Chemistry, 2010, 56, 388-390.	1.5	13
225	Association Between Markers of Inflammation and Total Stroke by Hypertensive Status Among Women. American Journal of Hypertension, 2016, 29, 1117-1124.	1.0	13
226	Effects of analgesics on bone mineral density: A longitudinal analysis of the prospective SWAN cohort with threeâ€group matching weights. Pharmacoepidemiology and Drug Safety, 2018, 27, 182-190.	0.9	13
227	Stepped-wedge randomised trial to evaluate population health intervention designed to increase appropriate anticoagulation in patients with atrial fibrillation. BMJ Quality and Safety, 2019, 28, 835-842.	1.8	13
228	Comparison of Questionnaire-Based Breast Cancer Prediction Models in the Nurses' Health Study. Cancer Epidemiology Biomarkers and Prevention, 2019, 28, 1187-1194.	1.1	12
229	Reuse of data sources to evaluate drug safety signals: When is it appropriate?. Pharmacoepidemiology and Drug Safety, 2018, 27, 567-569.	0.9	11
230	Effect of Low-Dose Methotrexate on eGFR and Kidney Adverse Events: A Randomized Clinical Trial. Journal of the American Society of Nephrology: JASN, 2021, 32, 3197-3207.	3.0	11
231	MULTIVARIATE METHODS FOR CLUSTERED ORDINAL DATA WITH APPLICATIONS TO SURVIVAL ANALYSIS. Statistics in Medicine, 1997, 16, 357-372.	0.8	10
232	Multiple imputation to estimate the association between eyes in disease progression with interval-censored data. Statistics in Medicine, 2004, 23, 3307-3318.	0.8	10
233	Commentary: Genes as instruments for evaluation of markers and causes. International Journal of Epidemiology, 2006, 35, 932-934.	0.9	10
234	A Review of Disease Risk Scores and Their Application in Pharmacoepidemiology. Current Epidemiology Reports, 2016, 3, 277-284.	1.1	10

#	Article	IF	Citations
235	Estimation of rank correlation for clustered data. Statistics in Medicine, 2017, 36, 2163-2186.	0.8	10
236	Quantifying bias reduction with fixed‐duration versus all‐available covariate assessment periods. Pharmacoepidemiology and Drug Safety, 2019, 28, 665-670.	0.9	10
237	Influence of blood pressure and blood pressure change on the risk of congestive heart failure in the elderly. Swiss Medical Weekly, 2010, 140, 202-8.	0.8	10
238	Time-Dependent Propensity Score for Assessing the Effect of Vaccine Exposure on Pregnancy Outcomes through Pregnancy Exposure Cohort Studies. International Journal of Environmental Research and Public Health, 2014, 11, 3074-3085.	1.2	9
239	Comparing Approaches to Measure Frailty in Medicare Data: Deficit-Accumulation Frailty Index Versus Phenotypic Frailty. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2018, 73, 989-990.	1.7	8
240	Tutorial on Biostatistics: Receiver-Operating Characteristic (ROC) Analysis for Correlated Eye Data. Ophthalmic Epidemiology, 2022, 29, 117-127.	0.8	8
241	Use of Covariates and Survey Wave to Adjust for Nonresponse. Biometrical Journal, 2004, 46, 579-588.	0.6	7
242	Effect of Rosuvastatin on Hemoglobin Levels in Patients With Anemia and Low-Grade Inflammation: A Post Hoc Analysis of the JUPITER Trial. Journal of Clinical Pharmacology, 2011, 51, 1483-1487.	1.0	7
243	Extensions of the Rosner-Colditz breast cancer prediction model to include older women and type-specific predicted risk. Breast Cancer Research and Treatment, 2017, 165, 215-223.	1.1	7
244	Characteristics of atypical postradiation vascular proliferation: A retrospective review of 193 patients. Journal of the American Academy of Dermatology, 2020, 83, 1447-1450.	0.6	7
245	Longitudinal Data Discontinuity in Electronic Health Records and Consequences for Medication Effectiveness Studies. Clinical Pharmacology and Therapeutics, 2021, , .	2.3	7
246	Editorial: Use of Propensity Scores To Design Observational Comparative Effectiveness Studies. Journal of the National Cancer Institute, 2017, 109, .	3.0	6
247	Inflammation, venous thromboembolism, and what we can do about it. European Heart Journal, 2018, 39, 3615-3617.	1.0	6
248	Vitamin D and omega-3 trial to prevent and treat diabetic kidney disease: Rationale, design, and baseline characteristics. Contemporary Clinical Trials, 2018, 74, 11-17.	0.8	6
249	A tool for empirical equipoise assessment in multigroup comparative effectiveness research. Pharmacoepidemiology and Drug Safety, 2019, 28, 934-941.	0.9	6
250	Interpretation of Mendelian Randomization Studies and the Search for Causal Pathways in Atherothrombosis: The Need for Caution. Metabolic Syndrome and Related Disorders, 2010, 8, 465-469.	0.5	5
251	Parity, Job Strain, and Cardiovascular Risk in the Women's Health Study. Current Cardiovascular Risk Reports, 2018, 12, 1.	0.8	5
252	Meeting Report: Translational Advances in Cancer Prevention Agent Development Meeting. Journal of Cancer Prevention, 2021, 26, 71-82.	0.8	4

#	Article	IF	Citations
253	Response by Eberly et al to Letter Regarding Article, "Identification of Racial Inequities in Access to Specialized Inpatient Heart Failure Care at an Academic Medical Center." Circulation: Heart Failure, 2020, 13, e007193.	1.6	3
254	The probability of sudden unexpected death in epilepsy given postictal prone position. Epilepsy and Behavior, 2021, 116, 107775.	0.9	3
255	Adverse effects related to methotrexate polyglutamate levels: adjudicated results from the cardiovascular inflammation reduction trial. Rheumatology, 2021, 60, 2963-2968.	0.9	3
256	Causal mediation analysis of the relationship of canakinumab's effect against subsequent gout flares and high-sensitivity C-reactive protein in <scp>CANTOS</scp>. Arthritis Care and Research, 2021, , .	1.5	3
257	Rosuvastatin, C-reactive protein, LDL cholesterol, and the JUPITER trial – Authors' reply. Lancet, The, 2009, 374, 26-27.	6.3	2
258	Response to Letter Regarding Article, "Influence of Systolic and Diastolic Blood Pressure on the Risk of Incident Atrial Fibrillation in Women." Circulation, 2010, 121, .	1.6	2
259	Study protocol for the dabigatran, apixaban, rivaroxaban, edoxaban, warfarin comparative effectiveness research study. Journal of Comparative Effectiveness Research, 2018, 7, 57-66.	0.6	2
260	Controlling Confounding in a Study of Oral Anticoagulants: Comparing Disease Risk Scores Developed Using Different Follow-Up Approaches. EGEMS (Washington, DC), 2019, 7, 27.	2.0	2
261	Incidence of venous thromboembolism following initiation of non-steroidal anti-inflammatory drugs in U.S. women. Rheumatology, 2020, 59, 2502-2511.	0.9	2
262	Evolving channeling in prescribing <scp>SGLT</scp>-2 inhibitors as first-line treatment for type 2 diabetes. Pharmacoepidemiology and Drug Safety, 2022, 31, 566-576.	0.9	2
263	Model Misspecification When Excluding Instrumental Variables from PS Models in Settings Where Instruments Modify the Effects of Covariates on Treatment. Epidemiologic Methods, 2014, 3, 83-96.	0.8	1
264	Non-Vitamin K Antagonist Oral Anticoagulants and Angioedema: A Cohort and Case-Crossover Study. Drug Safety, 2019, 42, 1355-1363.	1.4	1
265	COMPARATIVE PERFORMANCE OF FOUR CLAIMS-BASED FRAILTY MEASURES IN THE UNITED STATES MEDICARE DATA. Innovation in Aging, 2019, 3, S684-S685.	0.0	1
266	Changing predictors of statin initiation in US women over two decades. Pharmacoepidemiology and Drug Safety, 2019, 28, 305-314.	0.9	1
267	Improving measurement of binary covariates in claims data: A simulation study. Pharmacoepidemiology and Drug Safety, 2020, 29, 1093-1100.	0.9	1
268	Age-related macular degeneration in a randomized trial of selenium and vitamin E in men: the Select Eye Endpoints (SEE) study (SWOG S0000B). Acta Ophthalmologica, 2021, 99, e285-e287.	0.6	1
269	Methodological issues affecting estimates of bleeding risks and consequences after venous thromboembolism. Thrombosis and Haemostasis, 2009, 101, 797-8.	1.8	1
270	A multi-state survival model for time to breast cancer mortality among a cohort of initially disease-free women. Cancer Epidemiology Biomarkers and Prevention, 0, , .	1.1	1

#	Article	IF	Citations
271	Response to Letter Regarding Article, â€œEffects of Random Allocation to Vitamin E Supplementation on the Occurrence of Venous Thromboembolism: Report From the Womenâ€™s Health Studyâ€ Circulation, 2008, 117, .	1.6	0
272	Abstract 16278: Discordant Lipid Phenotype and Other Determinants of Statin Response in the Pravastatin Inflammation/crp Evaluation (PRINCE) Trial. Circulation, 2020, 142, .	1.6	0